Skip to main content

NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

To learn if psilocybin can help to prevent or decrease the severity of chemotherapy-induced peripheral neuropathy (CIPN) in patients who are receiving chemotherapy for the treatment of breast, colorectal, and In this study, psilocybin is being compared to standard supportive care and to a placebo.

Status
planned
Phase
Phase 2
Institution
M.D. Anderson Cancer Center
Principal investigator
Moran Amit, MD
Start date
2026-11-04
End date
2031-01-31
Registry ID
NCT07227909

View trial record

Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.